-

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 4, 2025. The detailed results of the votes received by proxy are as follows:

Election of Directors

Director Nominees

NUMBER OF SHARES

PERCENTAGE OF VOTES CAST

FOR

WITHHELD

FOR

WITHHELD

Daniel N. Chicoine

5,432,232

301,172

94.75%

5.25%

Anthony E. Dobranowski

5,455,219

278,185

95.15%

4.85%

John C. London

5,427,266

306,138

94.66%

5.34%

Deborah Shannon-Trudeau

5,463,225

270,179

95.29%

4.71%

Serge Verreault

5,490,982

242,422

95.77%

4.23%

Reappointment of External Auditors

Outcome

NUMBER OF SHARES

PERCENTAGE OF VOTES CAST

FOR

WITHHELD

FOR

WITHHELD

Ernst & Young LLP reappointed

6,388,758

49,767

99.23%

0.77%

Approval of the Continuation of Crescita’s Shareholder Rights Plan

Outcome

NUMBER OF SHARES

PERCENTAGE OF VOTES CAST

FOR

AGAINST

FOR

AGAINST

Shareholder Rights Plan approved

5,481,368

252,036

95.60%

4.40%

About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.

Source: Crescita Therapeutics

Contacts

FOR MORE INFORMATION, PLEASE CONTACT:
Linda Kisa, CPA, CA
Vice-President, Reporting and Corporate Affairs
Email: lkisa@crescitatx.com

Industry:

Crescita Therapeutics Inc.

TSX:CTX
Release Versions
English

Contacts

FOR MORE INFORMATION, PLEASE CONTACT:
Linda Kisa, CPA, CA
Vice-President, Reporting and Corporate Affairs
Email: lkisa@crescitatx.com

More News From Crescita Therapeutics Inc.

Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis®

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities, today announced that it has, by mutual agreement, terminated its commercialization and development license agreement with CROMA Pharma GmbH (“Croma”), that granted Croma exclusive rights to market Pliaglis® in Germany, the United Kingdom, Ireland, S...

Crescita Reports First Quarter 2025 Results

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2025 (“Q1-2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting S...

Crescita Reports Q4 and Fiscal 2024 Results

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2024 (“Q4-2024” and “F2024”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued b...
Back to Newsroom